Indication
MASH / NASH
The MASH / NASH pipeline: 31 tracked drugs, 2 approved for this indication.
2 approved / phase 46 Phase 32 Phase 2/313 Phase 22 Phase 1/24 Phase 12 preclinical / unstaged
Compare the share prices of listed companies in MASH / NASH →
Total attributable cost
$303.2B
$20,346/patient
Drug spend
$1.0B
$64/patient
0% of total cost is drugs
All diagnosed and undiagnosed adult MASH/NASH severity strata (US estimate; upper-bound prevalence context) · US